Joshua Cohen Sells 29,933 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Key Points

• CEO Joshua Cohen sold 29,933 shares of Amylyx Pharmaceuticals (AMLX) at an average price of $14.35, totaling approximately $429,538.
• Amylyx Pharmaceuticals reported a loss of $0.46 earnings per share, missing analysts' expectations, while institutional investors control 95.84% of the company's stock.
• The stock has fluctuated between a one-year low of $2.60 and a high of $15.15, with a current trading price of $13.29.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Joshua Cohen sold 29,933 shares of the firm's stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $14.35, for a total value of $429,538.55. Following the transaction, the chief executive officer owned 3,325,347 shares in the company, valued at approximately $47,718,729.45. This trade represents a 0.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Amylyx Pharmaceuticals Stock Performance

AMLX traded down $0.71 during midday trading on Thursday, reaching $13.29. 3,330,605 shares of the company were exchanged, compared to its average volume of 1,254,741. Amylyx Pharmaceuticals, Inc. has a one year low of $2.60 and a one year high of $15.15. The stock has a market capitalization of $1.19 billion, a P/E ratio of -5.32 and a beta of -0.34. The stock's 50-day simple moving average is $10.09 and its 200 day simple moving average is $6.87.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.02). On average, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $28,000. Valeo Financial Advisors LLC acquired a new stake in Amylyx Pharmaceuticals in the 1st quarter valued at approximately $35,000. R Squared Ltd raised its position in Amylyx Pharmaceuticals by 99.9% in the 1st quarter. R Squared Ltd now owns 12,736 shares of the company's stock valued at $45,000 after buying an additional 6,366 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets raised its position in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after buying an additional 5,904 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.

Wall Street Analyst Weigh In

AMLX has been the topic of a number of recent analyst reports. UBS Group upgraded Amylyx Pharmaceuticals to a "hold" rating in a report on Tuesday, June 24th. Jefferies Financial Group started coverage on Amylyx Pharmaceuticals in a research report on Tuesday, June 24th. They set a "hold" rating on the stock. Guggenheim raised their price target on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, September 15th. The Goldman Sachs Group raised their price target on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, September 16th. Finally, Wall Street Zen raised Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $14.50.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.